Emerging Company Profile
Wugen: deploying memory NK cells against cancer
And turning allogeneic CAR T cells against T cell malignancies
With a license to a potent NK cell subtype and a body of clinical data, Wugen is advancing its memory NK cells to the clinic.
Wugen is adding a new subset of NK cells to the cell therapy toolkit with its memory NK cell approach, which may lead to high antitumor efficacy without requiring